Xencor (XNCR) Return on Capital Employed (2014 - 2026)
Xencor (XNCR) posted quarterly Return on Capital Employed of 28.96% for Q1 2026, down 908.0% year-over-year from 3.58% in Q1 2025, and down 26.64% quarter-over-quarter from 22.87% in Q4 2025.
Xencor (XNCR) Return on Capital Employed (2014 - 2026) Analysis & Trends
Xencor (XNCR) has reported Return on Capital Employed for 13 consecutive years, with 28.96% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 908.0% year-over-year to 28.96%; the TTM figure through Mar 2026 stood at 28.96% (down 908.0% YoY), while the FY2025 annual figure was 21.7%, down 122.0% from the prior year.
- Return on Capital Employed slipped to 28.96% in Q1 2026 per XNCR's latest filing, from 22.87% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 10.91% in Q1 2022 and bottomed at 28.96% in Q1 2026.
- Historically, Return on Capital Employed has averaged 14.89% across 5 years, with a median of 19.62% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 2491 bps — and 2023, when it sank 3325 bps.
- Xencor's Return on Capital Employed stood at 10.62% in 2022, then plunged by 56 bps to 16.59% in 2023, then retreated by 21 bps to 20.08% in 2024, then fell by 14 bps to 22.87% in 2025, then decreased by 27 bps to 28.96% in 2026.
- Business Quant data shows XNCR's Return on Capital Employed at 28.96% in Q1 2026, 22.87% in Q4 2025, and 17.4% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -33.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.29% |
| Mar 31, 2026 | -28.96% |
| Dec 31, 2025 | -22.87% |
| Sep 30, 2025 | -17.40% |
| Jun 30, 2025 | -18.18% |
| Mar 31, 2025 | -19.88% |
| Dec 31, 2024 | -20.08% |
| Sep 30, 2024 | -23.22% |
| Jun 30, 2024 | -19.62% |
| Mar 31, 2024 | -14.69% |
| Dec 31, 2023 | -16.59% |
| Sep 30, 2023 | -20.35% |
| Jun 30, 2023 | -22.47% |
| Mar 31, 2023 | -22.33% |
| Dec 31, 2022 | -10.62% |
| Sep 30, 2022 | 6.87% |
| Jun 30, 2022 | 6.26% |
| Mar 31, 2022 | 10.91% |
| Dec 31, 2021 | 6.28% |
| Sep 30, 2021 | -9.44% |